Ruxolitinib treatment in myelofibrosis and polycythemia vera causes suboptimal humoral immune response following standard and booster vaccination with BNT162b2 mRNA COVID-19 vaccine

Patients affected by myelofibrosis (MF) or polycythemia vera (PV) and treated with ruxolitinib are at high risk for severe coronavirus disease 2019. Now a vaccine against the virus SARS-CoV-2, which is responsible for this disease, is available. However, sensitivity to vaccines is usually lower in t...

Descripción completa

Detalles Bibliográficos
Autores principales: Palumbo, Giuseppe A., Cambria, Daniela, La Spina, Enrico, Duminuco, Andrea, Laneri, Antonio, Longo, Anna, Vetro, Calogero, Giallongo, Sebastiano, Romano, Alessandra, Di Raimondo, Francesco, Tibullo, Daniele, Giallongo, Cesarina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9974162/
https://www.ncbi.nlm.nih.gov/pubmed/36865808
http://dx.doi.org/10.3389/fonc.2023.1117815

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9974162/
https://www.ncbi.nlm.nih.gov/pubmed/36865808
http://dx.doi.org/10.3389/fonc.2023.1117815

Ejemplares similares